# | Title | Journal | Year | Citations |
---|
1 | Targeting PI3K/Akt/mTOR Signaling in Cancer | Frontiers in Oncology | 2014 | 1,077 |
2 | Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations | Frontiers in Oncology | 2018 | 926 |
3 | Implications of the Hybrid Epithelial/Mesenchymal Phenotype in Metastasis | Frontiers in Oncology | 2015 | 581 |
4 | Role of Matrix Metalloproteinases in Angiogenesis and Cancer | Frontiers in Oncology | 2019 | 570 |
5 | Lactate in the Regulation of Tumor Microenvironment and Therapeutic Approaches | Frontiers in Oncology | 2019 | 522 |
6 | Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi | Frontiers in Oncology | 2018 | 506 |
7 | Radiation-induced brain injury: A review | Frontiers in Oncology | 2012 | 501 |
8 | Targeting PI3K/mTOR Signaling in Cancer | Frontiers in Oncology | 2014 | 450 |
9 | Trastuzumab: Updated Mechanisms of Action and Resistance in Breast Cancer | Frontiers in Oncology | 2012 | 427 |
10 | Tumor-Associated Macrophages: Recent Insights and Therapies | Frontiers in Oncology | 2020 | 401 |
11 | DNA Methyltransferases: A Novel Target for Prevention and Therapy | Frontiers in Oncology | 2014 | 393 |
12 | Targeting Macrophages in Cancer: From Bench to Bedside | Frontiers in Oncology | 2018 | 385 |
13 | Evaluating the Polarization of Tumor-Associated Macrophages Into M1 and M2 Phenotypes in Human Cancer Tissue: Technicalities and Challenges in Routine Clinical Practice | Frontiers in Oncology | 2019 | 385 |
14 | Tumor Associated Neutrophils. Their Role in Tumorigenesis, Metastasis, Prognosis and Therapy | Frontiers in Oncology | 2019 | 384 |
15 | Mitochondrial Dysfunction in Cancer | Frontiers in Oncology | 2013 | 382 |
16 | The KEAP1–NRF2 System in Cancer | Frontiers in Oncology | 2017 | 370 |
17 | Cancer-Associated Fibroblasts as Another Polarized Cell Type of the Tumor Microenvironment | Frontiers in Oncology | 2014 | 363 |
18 | Getting to Know Ovarian Cancer Ascites: Opportunities for Targeted Therapy-Based Translational Research | Frontiers in Oncology | 2013 | 358 |
19 | PTEN: Multiple Functions in Human Malignant Tumors | Frontiers in Oncology | 2015 | 356 |
20 | Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification | Frontiers in Oncology | 2017 | 343 |
21 | Radiomic Machine-Learning Classifiers for Prognostic Biomarkers of Head and Neck Cancer | Frontiers in Oncology | 2015 | 318 |
22 | Chemical and Pharmacological Aspects of Caffeic Acid and Its Activity in Hepatocarcinoma | Frontiers in Oncology | 2019 | 309 |
23 | Altered Tumor-Cell Glycosylation Promotes Metastasis | Frontiers in Oncology | 2014 | 308 |
24 | Exploratory Study to Identify Radiomics Classifiers for Lung Cancer Histology | Frontiers in Oncology | 2016 | 306 |
25 | The Keap1–Nrf2 system in cancers: stress response and anabolic metabolism | Frontiers in Oncology | 2012 | 305 |
26 | Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications | Frontiers in Oncology | 2018 | 305 |
27 | Ultra-High Dose Rate (FLASH) Radiotherapy: Silver Bullet or Fool's Gold? | Frontiers in Oncology | 2019 | 302 |
28 | Microtubules and Their Role in Cellular Stress in Cancer | Frontiers in Oncology | 2014 | 296 |
29 | The Global Landscape of EBV-Associated Tumors | Frontiers in Oncology | 2019 | 289 |
30 | Phosphoinositide 3-Kinase/Akt Signaling and Redox Metabolism in Cancer | Frontiers in Oncology | 2018 | 283 |
31 | “Do We Know Jack” About JAK? A Closer Look at JAK/STAT Signaling Pathway | Frontiers in Oncology | 2018 | 283 |
32 | Cell Adhesion and Matrix Stiffness: Coordinating Cancer Cell Invasion and Metastasis | Frontiers in Oncology | 2018 | 268 |
33 | The Role of the Extracellular Matrix and Its Molecular and Cellular Regulators in Cancer Cell Plasticity | Frontiers in Oncology | 2018 | 267 |
34 | Clinical Overview of MDM2/X-Targeted Therapies | Frontiers in Oncology | 2016 | 266 |
35 | Recent Advances in the Treatment of Breast Cancer | Frontiers in Oncology | 2018 | 263 |
36 | Endoplasmic Reticulum Stress, Unfolded Protein Response, and Cancer Cell Fate | Frontiers in Oncology | 2017 | 261 |
37 | Control of the Immune Response by Pro-Angiogenic Factors | Frontiers in Oncology | 2014 | 260 |
38 | Pyruvate Kinase M2 and Cancer: The Role of PKM2 in Promoting Tumorigenesis | Frontiers in Oncology | 2020 | 260 |
39 | Radiation as an immunological adjuvant: current evidence on dose and fractionation | Frontiers in Oncology | 2012 | 259 |
40 | Radiation-Induced Oral Mucositis | Frontiers in Oncology | 2017 | 257 |
41 | Targeting Oncogenic Mutant p53 for Cancer Therapy | Frontiers in Oncology | 2015 | 249 |
42 | Fluorescence-Guided Surgery | Frontiers in Oncology | 2017 | 249 |
43 | CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future | Frontiers in Oncology | 2020 | 247 |
44 | Vascular Permeability and Drug Delivery in Cancers | Frontiers in Oncology | 2013 | 246 |
45 | Immuno-Oncology: Emerging Targets and Combination Therapies | Frontiers in Oncology | 2018 | 244 |
46 | Transforming Growth Factor-β-Induced Cell Plasticity in Liver Fibrosis and Hepatocarcinogenesis | Frontiers in Oncology | 2018 | 243 |
47 | Past, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody Therapy | Frontiers in Oncology | 2018 | 238 |
48 | Gene Therapy Leaves a Vicious Cycle | Frontiers in Oncology | 2019 | 236 |
49 | Radiation-Induced Heart Disease: Pathologic Abnormalities and Putative Mechanisms | Frontiers in Oncology | 2015 | 232 |
50 | Prognostic Genes of Breast Cancer Identified by Gene Co-expression Network Analysis | Frontiers in Oncology | 2018 | 231 |